Since the start of the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic, there has been rapid progress with understanding disease, clinical phenotypes and biology, improving treatment and implementing vaccination trials. Data is accumulating about the impact of COVID-19 for patients with Inborn Errors of Immunity (IEI). The purpose of this statement is to summarise our state of knowledge and set out ESID’s current guidance for professionals in the IEI community in Europe. We will update this statement as evidence emerges.
Together with IPOPI, INGID, APSID, ASID, ARAPID, CIS, LASID, SEAPID we have worked on a joint statement to provide guidance in advising patients with primary immunodeficiency under our care in the current COVID-19 context.
Date: Wednesday 27th October
Time: 14:00 CEST
Dear ESID Member,
We and ESID Board want to pay your immediate attention to an ongoing independent survey by the COVID Human Genetic Effort on the clinical characteristics of SARS-CoV-2 infection in patients with GATA2 deficiency.
We consider this an important and timely survey. If your center has such patients, please consider, whether your center could participate in it.
Date: Tuesday 18th May
Time: 17:30-18:30 CET